<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450164</url>
  </required_header>
  <id_info>
    <org_study_id>KT-2000</org_study_id>
    <nct_id>NCT00450164</nct_id>
  </id_info>
  <brief_title>Secondary Prophylaxis After Variceal Bleeding in Non-Responders</brief_title>
  <acronym>KT-2000</acronym>
  <official_title>Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled and randomized study comparing combined treatment (nadolol and endoscopic&#xD;
      ligation) versus nadolol associated with isosorbide mononitrate or prazosin according to&#xD;
      hemodynamic response, in the prevention of esofagic verices rebleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present is a prospective, randomized, open label study, in parallel groups, in which the&#xD;
      patients with hemorrhage caused by esofagic varices will be randomized in two groups of&#xD;
      treatment, after control of acute hemorrhage.&#xD;
&#xD;
      All the patients included will receive standard medical treatment with beta - blockers and&#xD;
      endoscopic ligation of the esofagic varices.&#xD;
&#xD;
      The control group will be constituted by the patients assigned to receive endoscopic ligation&#xD;
      and nadolol (N).&#xD;
&#xD;
      The experimental group will be constituted by patients assigned to receive treatment&#xD;
      according to the hemodynamic response.&#xD;
&#xD;
      All patients included in the experimental group will receive pharmacologic treatment with&#xD;
      nadolol combined with Isosorbide Mononitrate (MNI) or Prazosin (PZ).&#xD;
&#xD;
      In both groups it will practice a basal hepatic hemodynamic study in the 4th-5th day after&#xD;
      their admitance (after achieve hemodynamic stability for at least 48 h and with hemorrhage&#xD;
      controlled) and a second control hepatic hemodynamic study 3-4 weeks after the beginning of&#xD;
      the pharmacologic treatment, once adjusted doses.&#xD;
&#xD;
      In the experimental group, the responders to N + MNI will keep on this treatment, but&#xD;
      nonrespondent in the hemodynamic study will switch treatment to N + PZ and a third hepatic&#xD;
      hemodynamic study will be performed 3 to 4 weeks after the dosage adjustement.&#xD;
&#xD;
      The randomization will be stratified according to the degree of hepatic failure measured by&#xD;
      Child-Pugh classification (classes A and B versus C) The design is random to avoid bias in&#xD;
      the selection of the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compared efficacy (at least 6 moths of follow-up)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortallity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebleeding</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Gastrointestinal Hemorrhage</condition>
  <condition>Portal Hypertension</condition>
  <condition>Cirrhosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>esofagic varices ligation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadolol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide mononitrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any Patient with endoscopically assessed Variceal Bleeding (esofagic and gastric)&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Patient agreement to be included in the study onsentiment signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any associated comorbidity with life expectancy lesser than 6 months&#xD;
&#xD;
          -  Patient refusement to be included in the study.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Failure to control acute bleeding&#xD;
&#xD;
          -  Previous prophylaxis treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candid - Villanueva, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad de Sangrantes, HSCSP</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <last_update_submitted>March 20, 2007</last_update_submitted>
  <last_update_submitted_qc>March 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2007</last_update_posted>
  <keyword>Variceal bleeding</keyword>
  <keyword>Secondary profilaxis</keyword>
  <keyword>Hemodynamic</keyword>
  <keyword>Portal hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadolol</mesh_term>
    <mesh_term>Prazosin</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

